A Critique of the Drug Discovery and Phase 3 Clinical Programs Targeting the Amyloid Hypothesis for Alzheimer Disease

Detalles Bibliográficos
Autores principales: Karran, Eric, Hardy, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204160/
https://www.ncbi.nlm.nih.gov/pubmed/24853080
http://dx.doi.org/10.1002/ana.24188
_version_ 1782340511778996224
author Karran, Eric
Hardy, John
author_facet Karran, Eric
Hardy, John
author_sort Karran, Eric
collection PubMed
description
format Online
Article
Text
id pubmed-4204160
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BlackWell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-42041602014-10-21 A Critique of the Drug Discovery and Phase 3 Clinical Programs Targeting the Amyloid Hypothesis for Alzheimer Disease Karran, Eric Hardy, John Ann Neurol Reviews BlackWell Publishing Ltd 2014-08 2014-07-02 /pmc/articles/PMC4204160/ /pubmed/24853080 http://dx.doi.org/10.1002/ana.24188 Text en © 2014 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association. http://creativecommons.org/licenses/by/3.0/ This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Karran, Eric
Hardy, John
A Critique of the Drug Discovery and Phase 3 Clinical Programs Targeting the Amyloid Hypothesis for Alzheimer Disease
title A Critique of the Drug Discovery and Phase 3 Clinical Programs Targeting the Amyloid Hypothesis for Alzheimer Disease
title_full A Critique of the Drug Discovery and Phase 3 Clinical Programs Targeting the Amyloid Hypothesis for Alzheimer Disease
title_fullStr A Critique of the Drug Discovery and Phase 3 Clinical Programs Targeting the Amyloid Hypothesis for Alzheimer Disease
title_full_unstemmed A Critique of the Drug Discovery and Phase 3 Clinical Programs Targeting the Amyloid Hypothesis for Alzheimer Disease
title_short A Critique of the Drug Discovery and Phase 3 Clinical Programs Targeting the Amyloid Hypothesis for Alzheimer Disease
title_sort critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for alzheimer disease
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204160/
https://www.ncbi.nlm.nih.gov/pubmed/24853080
http://dx.doi.org/10.1002/ana.24188
work_keys_str_mv AT karraneric acritiqueofthedrugdiscoveryandphase3clinicalprogramstargetingtheamyloidhypothesisforalzheimerdisease
AT hardyjohn acritiqueofthedrugdiscoveryandphase3clinicalprogramstargetingtheamyloidhypothesisforalzheimerdisease
AT karraneric critiqueofthedrugdiscoveryandphase3clinicalprogramstargetingtheamyloidhypothesisforalzheimerdisease
AT hardyjohn critiqueofthedrugdiscoveryandphase3clinicalprogramstargetingtheamyloidhypothesisforalzheimerdisease

Ejemplares similares